Cranberry Extract

Cranberry extract suppresses cariogenic pathogenicity features of Streptococcus mutans and Candida albicans dual-species biofilms^[1].
Cranberry extract (20 h) protects HepG2 liver cells from t-BOOH-induced oxidative stress by reducing antioxidant enzyme over-activation, MDA levels, and modulating cell signaling pathways^[1].
Cranberry extract reduces pro-inflammatory mediator production and NF-κB activation in pre-incubated Caco-2/15 intestinal cells^[1].
Cranberry extract exerts anti-proliferative activity against KB nasopharyngeal carcinoma cells, but not against AW13516 tongue squamous cell carcinoma cells^[1].
Cranberry extract induces apoptosis in DU145 human prostate adenocarcinoma cells by increasing caspase-8 and caspase-9 activities^[1].
Cranberry extract (200 µg/mL; 48 h) exhibits selective antiproliferative activity against human KB, HT-29, HCT116, SW620, RWPE-1, RWPE-2, and 22Rv1 cancer cell lines^[2].
Cranberry Extract inhibits growth of vancomycin-resistant Enterococcus faecium, Pseudomonas aeruginosa, Staphylococcus aureus, and Escherichia coli^[4].
Cranberry extract (0.0050-0.10% (v/v); 4 h) significantly inhibits cupric sulfate-induced TBARS formation in isolated human LDL^[6].
Cranberry extract (0.0050-0.10% (v/v); 4 h) significantly reduces cupric sulfate-induced relative electrophoretic mobility of isolated human LDL^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.